ADAP Adaptimmune Therapeutics PLC

Price (delayed)

$5.735

Market cap

$896.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.96

Enterprise value

$864.52M

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform ...

Highlights
Adaptimmune Therapeutics's gross profit has surged by 179% YoY and by 71% QoQ
The company's revenue has surged by 179% YoY and by 71% QoQ
The company's quick ratio fell by 36% YoY and by 32% QoQ
Adaptimmune Therapeutics's equity has decreased by 32% YoY and by 10% from the previous quarter

Key stats

What are the main financial stats of ADAP
Market
Shares outstanding
156.4M
Market cap
$896.96M
Enterprise value
$864.52M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.21
Price to sales (P/S)
143.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
138.9
Earnings
Revenue
$6.22M
EBIT
-$148.44M
EBITDA
-$142.01M
Free cash flow
-$128.34M
Per share
EPS
-$0.96
Free cash flow per share
-$0.82
Book value per share
$1.78
Revenue per share
$0.04
TBVPS
$2.49
Balance sheet
Total assets
$389.79M
Total liabilities
$111.85M
Debt
$22.65M
Equity
$277.94M
Working capital
$295.93M
Liquidity
Debt to equity
0.08
Current ratio
8.15
Quick ratio
7.05
Net debt/EBITDA
0.23
Margins
EBITDA margin
-2,281.6%
Gross margin
100%
Net margin
-2,392%
Operating margin
-2,419.5%
Efficiency
Return on assets
-34.4%
Return on equity
-45.6%
Return on invested capital
-41.4%
Return on capital employed
-42.6%
Return on sales
-2,384.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADAP stock price

How has the Adaptimmune Therapeutics stock price performed over time
Intraday
-1.46%
1 week
4.27%
1 month
11.36%
1 year
-26.85%
YTD
6.4%
QTD
34.62%

Financial performance

How have Adaptimmune Therapeutics's revenue and profit performed over time
Revenue
$6.22M
Gross profit
$6.22M
Operating income
-$150.59M
Net income
-$148.88M
Gross margin
100%
Net margin
-2,392%
Adaptimmune Therapeutics's gross profit has surged by 179% YoY and by 71% QoQ
The company's revenue has surged by 179% YoY and by 71% QoQ
ADAP's operating margin has soared by 59% YoY and by 38% QoQ
The net margin has surged by 58% year-on-year and by 38% since the previous quarter

Growth

What is Adaptimmune Therapeutics's growth rate over time

Valuation

What is Adaptimmune Therapeutics stock price valuation
P/E
N/A
P/B
3.21
P/S
143.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
138.9
Adaptimmune Therapeutics's EPS has increased by 16% YoY
Adaptimmune Therapeutics's equity has decreased by 32% YoY and by 10% from the previous quarter
ADAP's price to book (P/B) is 21% higher than its last 4 quarters average of 2.7 and 16% higher than its 5-year quarterly average of 2.8
The company's revenue has surged by 179% YoY and by 71% QoQ
The P/S is 36% below the last 4 quarters average of 229.2 but 35% above the 5-year quarterly average of 108.2

Efficiency

How efficient is Adaptimmune Therapeutics business performance
Adaptimmune Therapeutics's ROS has soared by 58% YoY and by 38% from the previous quarter
The company's return on invested capital rose by 33% YoY but it fell by 11% QoQ
The return on equity is up by 22% year-on-year but it has declined by 17% since the previous quarter
Adaptimmune Therapeutics's return on assets has increased by 19% YoY but it has decreased by 14% QoQ

Dividends

What is ADAP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADAP.

Financial health

How did Adaptimmune Therapeutics financials performed over time
The company's quick ratio fell by 36% YoY and by 32% QoQ
ADAP's current ratio is down by 31% YoY and by 29% QoQ
The debt is 92% smaller than the equity
ADAP's debt to equity is up by 33% year-on-year and by 14% since the previous quarter
Adaptimmune Therapeutics's equity has decreased by 32% YoY and by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.